Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Efficacy and Safety of Third Generation Tyrosine Kinase Inhibitors Combined With Azacitidine and B-cell Lymphoma-2 Inhibitor in Patients With Myeloid Blast Phase Chronic Myeloid Leukemia

NCT06390306 is registered in ClinicalTrials.gov with Peking University People's Hospital as lead sponsor.

NCT NCT06390306
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06390306 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Efficacy and Safety of Third Generation Tyrosine Kinase Inhibitors Combined With Azacitidine and B-cell Lymphoma-2 Inhibitor in Patients With Myeloid Blast Phase Chronic Myeloid Leukemia
Lead sponsor
Peking University People's Hospital
Phase
Observational
Overall status
Recruiting
Start date
July 1, 2024
Completion date
December 1, 2027
Enrollment
30 (estimated)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

chronic myeloid leukemia